The fibrinogen - 148 C/T polymorphism influences inflammatory response in experimental endotoxemia in vivo

Thrombosis Research

Volumn 120, Issue 5, 2007, Pages 727-731

  Kovar, Florian M ^a   Marsik, Claudia ^a   Jilma, Bernd ^a   Mannhalter, Christine ^a   Quehenberger, Peter ^a   Handler, Silvia ^a   Wagner, Oswald F ^a   Endler, Georg ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

148 C T polymorphism; Endotoxemia in vivo; Fibrinogen ; Human; Inflammatory response

Indexed keywords

CYTOSINE; D DIMER; EDETIC ACID; ENDOTOXIN; FIBRINOGEN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PROTHROMBIN; THYMINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALLELE; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CYTOKINE RELEASE; ENDOTOXEMIA; FIBRINOGEN GENE; GENE; GENE LOCUS; GENE SEQUENCE; HETEROZYGOTE; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; MALE; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; VEIN PUNCTURE; VOLUNTEER;

ADULT; EDETIC ACID; ENDOTOXEMIA; FIBRINOGEN; HUMANS; INFLAMMATION; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MALE; MODELS, BIOLOGICAL; MUTAGENESIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); TUMOR NECROSIS FACTOR-ALPHA;

EID: 34547947060     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2006.12.007     Document Type: Article

References (28)

1. Kamath S., and Lip G.Y. Fibrinogen: biochemistry, epidemiology and determinants. Qjm 96 10 (2003) 711-729
2. Blake G.J., Schmitz C., Lindpaintner K., and Ridker P.M. Mutation in the promoter region of the beta-fibrinogen gene and the risk of future myocardial infarction, stroke and venous thrombosis. Eur Heart J 22 24 (2001) 2262-2266
3. Anderson G.M., Shaw A.R., and Shafer J.A. Functional characterization of promoter elements involved in regulation of human B beta-fibrinogen expression. Evidence for binding of novel activator and repressor proteins. J Biol Chem 268 30 (1993) 22650-22655
4. Dalmon J., Laurent M., and Courtois G. The human beta fibrinogen promoter contains a hepatocyte nuclear factor 1-dependent interleukin-6-responsive element. Mol Cell Biol 13 2 (1993) 1183-1193
5. Huber P., Dalmon J., Courtois G., Laurent M., Assouline Z., and Marguerie G. Characterization of the 5-flanking region for the human fibrinogen beta gene. Nucleic Acids Res 15 4 (1987) 1615-1625
6. Behague I., Poirier O., Nicaud V., Evans A., Arveiler D., Luc G., et al. Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study. Etude Cas-Temoins sur l'Infarctus du Myocarde. Circulation 93 3 (1996) 440-449
7. Humphries S.E., Cook M., Dubowitz M., Stirling Y., and Meade T.W. Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet 1 8548 (1987) 1452-1455
8. Thomas A., Lamlum H., Humphries S., and Green F. Linkage disequilibrium across the fibrinogen locus as shown by five genetic polymorphisms, G/A-455 (HaeIII), C/T-148 (HindIII/AluI), T/G+1689 (AvaII), and BclI (beta-fibrinogen) and TaqI (alpha-fibrinogen), and their detection by PCR. Hum Mutat 3 1 (1994) 79-81
9. Bara L., Nicaud V., Tiret L., Cambien F., and Samama M.M. Expression of a paternal history of premature myocardial infarction on fibrinogen, factor VIIC and PAI-1 in European offspring - the EARS study. European Atherosclerosis Research Study Group. Thromb Haemost 71 4 (1994) 434-440
10. Hamsten A., Iselius L., de Faire U., and Blomback M. Genetic and cultural inheritance of plasma fibrinogen concentration. Lancet 2 8566 (1987) 988-991
11. Livshits G., Blettner M., Graff E., Hoting I., Wahrendorf J., Brunner D., et al. Tel Aviv-Heidelberg three-generation offspring study: genetic determinants of apolipoprotein A1 and apolipoprotein B. Am J Med Genet 57 3 (1995) 410-416
12. Berg K., and Kierulf P. DNA polymorphisms at fibrinogen loci and plasma fibrinogen concentration. Clin Genet 36 4 (1989) 229-235
13. Reed T., Tracy R.P., and Fabsitz R.R. Minimal genetic influences on plasma fibrinogen level in adult males in the NHLBI twin study. Clin Genet 45 2 (1994) 71-77
14. de Maat M.P., Kastelein J.J., Jukema J.W., Zwinderman A.H., Jansen H., Groenemeier B., et al. - 455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen. REGRESS group. Arterioscler Thromb Vasc Biol 18 2 (1998) 265-271
15. Schmidt H., Schmidt R., Niederkorn K., Horner S., Becsagh P., Reinhart B., et al. Beta-fibrinogen gene polymorphism (C148→T) is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study. Arterioscler Thromb Vasc Biol. 18 3 (1998) 487-492
16. Yang Z., Li F., Liu G., Cai W., and Ling G. [The study of beta-fibrinogen gene - 455 G/A, - 148 C/T, 448 G/A polymorphisms and their association with plasma fibrinogen levels]. Zhonghua Xue Ye Xue Za Zhi 21 9 (2000) 463-465
17. Meade T.W., Mellows S., Brozovic M., Miller G.J., Chakrabarti R.R., North W.R., et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 2 8506 (1986) 533-537
18. Derhaschnig U., Bergmair D., Marsik C., Schlifke I., Wijdenes J., and Jilma B. Effect of interleukin-6 blockade on tissue factor-induced coagulation in human endotoxemia. Crit Care Med 32 5 (2004) 1136-1140
19. Endler G., Marsik C., Joukhadar C., Marculescu R., Mayr F., Mannhalter C., et al. The interleukin-6 G(- 174)C promoter polymorphism does not determine plasma interleukin-6 concentrations in experimental endotoxemia in humans. Clin Chem 50 1 (2004) 195-200
20. Jilma B., Marsik C., Kovar F., Wagner O.F., Jilma-Stohlawetz P., and Endler G. The single nucleotide polymorphism Ser128Arg in the E-selectin gene is associated with enhanced coagulation during human endotoxemia. Blood 105 6 (2005) 2380-2383
21. Marsik C., Halama T., Cardona F., Wlassits W., Mayr F., Pleiner J., et al. Regulation of Fas (APO-1, CD95) and Fas ligand expression in leukocytes during systemic inflammation in humans. Shock 20 6 (2003) 493-496
22. Jilma B., Marsik C., Mayr F., Graninger M.T., Taylor Jr. F.B., Ribel M.C., et al. Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans. Clin Pharmacol Ther 72 4 (2002) 403-410
23. Endler G., Funk M., Haering D., Lalouschek W., Lang W., Mirafzal M., et al. Is the factor XIII 34Val/Leu polymorphism a protective factor for cerebrovascular disease?. Br J Haematol 120 2 (2003) 310-314
24. Fox C.S., Larson M.G., Corey D., Feng D., Lindpaintner K., Polak J.F., et al. Absence of association between polymorphisms in the hemostatic factor pathway genes and carotid intimal medial thickness: the Framingham Heart Study. Stroke 35 3 (2004) e65-e67
25. Texereau J., Pene F., Chiche J.D., Rousseau C., and Mira J.P. Importance of hemostatic gene polymorphisms for susceptibility to and outcome of severe sepsis. Crit Care Med 32 5 Suppl (2004) S313-S319
26. Arbour N.C., Lorenz E., Schutte B.C., Zabner J., Kline J.N., Jones M., et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 25 2 (2000) 187-191
27. Hsieh K., Endler G., Lalouschek W., Haering D., and Mannhalter C. Simultaneous detection of co-segregating missense mutations of the Toll-like receptor 4. Biotechniques 33 4 (2002) :748, 52, 54
28. Kiechl S., Lorenz E., Reindl M., Wiedermann C.J., Oberhollenzer F., Bonora E., et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 347 3 (2002) 185-192